NEWS
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has been granted an extension by Nasdaq to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. The company now has until November 20, 2024 to evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading sessions. This extension does not immediately affect ENDRA's listing or trading status, and its stock will continue to trade under the symbol 'NDRA'.
Additionally, ENDRA reported that 91% of the Series B Warrants issued in their June 2024 public offering have been exercised, resulting in the issuance of 15,831,864 new shares of common stock. This brings the company's total outstanding common shares to 17,280,655.
Additionally, ENDRA reported that 91% of the Series B Warrants issued in their June 2024 public offering have been exercised, resulting in the issuance of 15,831,864 new shares of common stock. This brings the company's total outstanding common shares to 17,280,655.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2334Followers
106Following
24KVisitors
Follow
Seraphicall : Din they just have RS?? wtf again?
Jaguar8 OP Seraphicall : Yes![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Seraphicall Jaguar8 OP : This is ridiculous